Form 4: AtriCure Officer Sells 3,000 Shares Under 10b5-1 Plan

AtriCure's Chief Marketing & Strategy Officer, Justin J. Noznesky, sold 3,000 shares of common stock for a weighted average price of $36.30 per share.

Summary

• Justin J. Noznesky, the Chief Marketing & Strategy Officer of AtriCure, Inc. (ATRC), reported a transaction involving the company's common stock.
• The transaction, dated September 12, 2025, was a disposition (sale) of 3,000 shares of AtriCure common stock.
• The shares were sold at a weighted average price of $36.30 per share, with individual trades ranging from $36.28 to $36.36.
• Following this sale, Mr. Noznesky directly beneficially owns 83,964 shares of AtriCure common stock.
• The transaction was executed pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 4

Explanation: The sale of shares by a key executive, even if pre-planned under a 10b5-1 plan, generally carries a slightly negative to neutral sentiment as it removes insider capital from the company. The relatively small size of the sale (3,000 shares) compared to his remaining holdings (83,964 shares) mitigates a stronger negative score.

Positives

• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-scheduled sale rather than a reaction to immediate, undisclosed company news, which can mitigate negative market interpretations.

Negatives

• An insider, the Chief Marketing & Strategy Officer, sold 3,000 shares of company stock.
• Insider selling, even if pre-planned, can sometimes be interpreted by the market as a lack of confidence in the company's near-term prospects or a signal that the stock may be fully valued.

Risks

• Potential negative market perception due to insider selling, which could lead to cautious investor sentiment or minor downward pressure on the stock price.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may interpret the insider sale as a slightly negative signal, potentially leading to cautious sentiment or minor downward pressure on the stock price, despite the 10b5-1 plan.

Key Dates

Recommendation

While the sale by the Chief Marketing & Strategy Officer is a negative signal, it was executed under a Rule 10b5-1 plan, suggesting it was pre-scheduled and not a reaction to new adverse information. The number of shares sold (3,000) is also a small fraction of his remaining beneficial ownership (83,964 shares). Investors should monitor future insider activity and company performance, but this single transaction does not warrant a strong sell recommendation without additional negative catalysts.

Keywords

AtriCure, ATRC, Insider Trading, Form 4, Stock Sale, Executive Transaction, Justin J. Noznesky, Chief Marketing & Strategy Officer, 10b5-1 Plan